ASH 2022 | Real-world safety analysis of deferiprone in patients with MDS
Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, discusses challenges with iron chelation therapy in patients with myelodysplastic syndromes (MDS) and the need to improve treatment options for these patients. Dr Zeidan then shares some insights into a real-world analysis which investigated the safety of deferiprone in patients with MDS, using data from the US Safety Registry and a compassionate use program. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS, AbbVie, Takeda, Novartis, Aprea, Amgen, Otsuka, Gilead, Kura, Loxo Oncology, Geron, Mendus, Tyme: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees.
